GLP-1 Receptor Agonist interVentIon for poor responders afTer bariAtric Surgery: The GRAVITAS trial

Trial Profile

GLP-1 Receptor Agonist interVentIon for poor responders afTer bariAtric Surgery: The GRAVITAS trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Liraglutide (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms GRAVITAS
  • Most Recent Events

    • 11 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 22 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Mar 2016 Accrual to date is 8 % according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top